In the present study, we evaluated the effect and safety of adding oral hypoglycemic agents (metformin, SGLT2 inhibitor, or SGLT1/2 co-inhibitor) or injectable GLP-1 RAs to insulin therapy in patients with T1D. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.